GlobeNewswire

ERYTECH to Present Preclinical and Clinical Data on Use of Eryaspase in ALL and AML at EHA 2018

Share

LYON, France, June 15, 2018 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext:ERYP) (Nasdaq:ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that it will present preclinical data on the enzymatic activity of eryaspase (GRASPA®) for the treatment of relapsed acute lymphoblastic leukemia (ALL) and results of its Phase 2b clinical trial evaluating eryaspase (GRASPA®) for the treatment of acute myeloid leukemia (AML) at the European Hematology Association (EHA) Congress, being held June 14-17, 2018 in Stockholm, Sweden.

The preclinical eryaspase data will be presented during Poster Session I by Dr. Karine Aguera, ERYTECH's R&D Project Leader.

Poster Session: Preclinical Demonstration of Intracellular Activity of Asparaginase Encapsulated in Red Blood Cells Both in the Absence and in the Presence of Neutralizing Anti-Asparaginase Antibodies
Abstract #: PF160  
Lead Author: Karine Aguera  
Poster Session:  Poster Session I  
Location: Poster Area  
Date: Friday, June 15, 2018  
Time: 5:30 p.m. - 7:00 p.m. (CEST)  
     
In these in vivo and in vitro preclinical studies, eryaspase was effective in reducing L-asparagine (ASN) levels, both in the presence and absence of neutralizing anti-asparaginase antibodies (nAbs). The preclinical findings, confirmed in additional in  vitro experiments with eryaspase, support the theory that intra-cellular asparaginase activity may be responsible for the sustained effect on ASN reduction and can provide a more effective approach for the delivery of the L-asparaginase enzyme in patients with ALL, particularly in patients who have developed nAbs.
 
The AML Phase 2b trial data will be presented during Poster Session II by Dr. Mathilde Hunault of Centre Hospitalier Universitaire (CHU) d'Angers, France.
     
Poster Session: A Phase 2b of Eryaspase in Combination with Low-Dose Cytarabine as First-Line Therapy in Elderly Patients with Acute Myeloid Leukemia (ENFORCE - NCT01810705)
Abstract #: PS984  
Lead Author: Xavier Thomas  
Poster Session: Poster Session II  
Location: Poster Area  
Date: Saturday, June 16, 2018  
Time: 5:30 p.m. - 7:00 p.m. (CEST)  

The Phase 2b trial to evaluate the efficacy of eryaspase in elderly AML patients did not meet its primary endpoint to improve overall survival in this difficult-to-treat patient population. Patient selection is likely the most important factor, with enrolled patients remaining only briefly on treatment and unable to achieve a potential drug effect. Individualized risk stratification based on multi-parameter assessment tools and co-morbidity burden should be considered for older adults with AML participating in clinical trials. 

ERYTECH also has an abstract on the incidence of Venous Thromboembolism (VTE) in 125 ALL patients, treated in five studies.

Abstract: Venous Thromboembolism in Patients with Acute Lymphoblastic Leukemia (ALL) Treated with Eryaspase (L-Asparaginase Encapsulated in Red Blood Cells)

Abstract #:  PB1627  
Lead Author: Yves Bertrand  
Location: EHA Website Abstracts  

The findings of this study show that the risk of VTE with eryaspase treatment in ALL patients was low and observed primarily in adults. The low incidence of these events may be related to decreased incidence of impaired coagulation parameters.

All of the abstracts are currently available on the EHA website. The posters will be accessible on ERYTECH's website at the start of each poster session.

About ERYTECH:  www.erytech.com

Founded in Lyon, France in 2004, ERYTECH is a clinical-stage biopharmaceutical company developing innovative therapies for rare forms of cancer and orphan diseases. Leveraging its proprietary ERYCAPS platform, which uses a novel technology to encapsulate therapeutic drug substances inside red blood cells, ERYTECH has developed a pipeline of product candidates targeting markets with high unmet medical needs. ERYTECH's initial focus is on the development of products that target the altered amino acid metabolism of cancer cells, depriving them of nutrients necessary for their survival.

The Company's lead product, eryaspase, also known under the trade name GRASPA®, consists of an enzyme, L-asparaginase, encapsulated inside donor-derived red blood cells. L-asparaginase depletes asparagine, a naturally occurring amino acid essential for the survival and proliferation of cancer cells. L-asparaginase has been a standard component of multi-agent chemotherapy for the treatment of pediatric acute lymphoblastic leukemia (ALL), but side effects limit treatment compliance, especially in adults and patients with weak performance status.

Eryaspase demonstrated positive efficacy and safety results in various clinical trials in ALL, including in a Phase 2 study in patients over 55 years of age and in a Phase 2/3 trial in relapsed or refractory ALL patients, as well as in pancreatic cancer, where it achieved positive results in a Phase 2b trial of second-line treatment of patients with metastatic pancreatic cancer. ERYTECH is preparing for the launch of a pivotal Phase 3 clinical trial in second line pancreatic cancer and Phase 2 trials in first line pancreatic cancer and triple-negative breast cancer.

ERYTECH produces eryaspase at its own GMP-approved and operational manufacturing site in Lyon (France), and at a site for clinical production in Philadelphia (USA). ERYTECH has entered into licensing and distribution partnership agreements for eryaspase for ALL and AML in Europe with Orphan Europe (Recordati Group), and for ALL in Israel with TEVA, which will market the product under the GRASPA® brand name. The European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) have granted orphan drug designations for eryaspase for the treatment of ALL, AML and pancreatic cancer.

In addition to eryaspase, ERYTECH is developing erymethionase, methionine-Y-lyase encapsulated in red blood cells, to target cancer cells' amino acid metabolism and induce tumor starvation. ERYTECH is also exploring the use of its ERYCAPS platform for developing cancer immunotherapies (ERYMMUNE) and enzyme replacement therapies (ERYZYME).

ERYTECH is listed on the Nasdaq Global Select Market in the United States (ticker: ERYP) and on the Euronext regulated market in Paris (ISIN code: FR0011471135, ticker: ERYP). ERYTECH is part of the CAC Healthcare, CAC Pharma & Bio, CAC Mid & Small, CAC All Tradable, EnterNext PEA-PME 150 and Next Biotech indexes.

CONTACTS 

ERYTECH    
Naomi Eichenbaum
Director Investor Relations
NewCap
Julien Perez
Investor relations
Nicolas Merigeau
Media relations
   
+33 4 78 74 44 38
+1 917 312 5151
naomi.eichenbaum@erytech.com
+33 1 44 71 98 52
ERYTECH@newcap.eu

Forward-looking information

This press release contains forward-looking statements, forecasts and estimates with respect to the clinical results from and the development plans of eryaspase, business and regulatory strategy, and anticipated future performance of ERYTECH and of the market in which it operates. Certain of these statements, forecasts and estimates can be recognized by the use of words such as, without limitation, "believes", "anticipates", "expects", "intends", "plans", "seeks", "estimates", "may", "will" and "continue" and similar expressions. All statements contained in this press release other than statements of historical facts are forward-looking statements, including, without limitation, statements regarding the potential of ERYTECH's product pipeline, its clinical development and regulatory plans for eryaspase, the timing of ERYTECH's clinical studies and trials and announcements of data from those studies and trials, and the contents and timing of decisions by the FDA and EMA regarding ERYTECH's product candidates. Such statements, forecasts and estimates are based on various assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable when made but may or may not prove to be correct. Actual events are difficult to predict and may depend upon factors that are beyond ERYTECH's control. There can be no guarantees with respect to pipeline product candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful. Therefore, actual results may turn out to be materially different from the anticipated future results, performance or achievements expressed or implied by such statements, forecasts and estimates. Further description of these risks, uncertainties and other risks can be found in the Company's regulatory filings with the French Autorité des Marchés Financiers (AMF), the Company's Securities and Exchange Commission (SEC) filings and reports, including in the Company's 2017 Document de Référence filed with the AMF in April 2018 and in the Company's Annual Report on Form 20-F filed with the SEC on April 24, 2018, as amended on May 23, 2018, and future filings and reports by the Company. Given these uncertainties, no representations are made as to the accuracy or fairness of such forward-looking statements, forecasts and estimates. Furthermore, forward-looking statements, forecasts and estimates only speak as of the date of this press release. Readers are cautioned not to place undue reliance on any of these forward-looking statements. ERYTECH disclaims any obligation to update any such forward-looking statement, forecast or estimates to reflect any change in ERYTECH's expectations with regard thereto, or any change in events, conditions or circumstances on which any such statement, forecast or estimate is based, except to the extent required by law




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Erytech Pharma S.A. via Globenewswire

About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

Value Asset Management PLC Announces Launch of GBP 1 Million Equity Private Placement22.8.2019 19:09:00 CESTPress release

Value Asset Management PLC Announces Launch of GBP 1 Million Equity Private Placement London, August 22nd, 2019. Value Asset Management PLC (VAM PLC) VAM PLC, a residential property developer within the Republic of Ireland is pleased to announce the launch of an equity private placement for gross proceeds of up to GBP 1 million. The private placement will be for up to 10,000,000 new shares in the company at a value of 10p each. Burlingtons Group, headquartered in London, have been formally engaged to conduct the placing which is intended to close by October 31st, 2019. Burlingtons Group has an extensive client and contact base across the globe through its international office base and represents many high-net-worth individuals, private investment funds, developers and banks. Burlingtons Legal LLP, which is also a member of Burlingtons Group, is separately engaged by VAM PLC to act as Bond Trustee to its “Value Asset Management PLC – 6.5% Secured Corporate Bonds 31/07/23 EUR 1 A” (ISIN:

DNO ASA: FAPE01 bond buyback22.8.2019 16:35:00 CESTPress release

Oslo, 22 August 2019 - DNO ASA, the Norwegian oil and gas operator, today purchased USD 3.0 million in nominal value of FAPE01 bonds (ISIN NO0010811268) originally issued by Faroe Petroleum plc, and renamed DNO North Sea plc. The bonds were purchased at a price of 107.00. Following the bond buyback and prior cancellations due to put option exercises, USD 65.2 million in nominal value of the FAPE01 bonds remain outstanding with DNO ASA holding the balance of USD 20.6 million. The FAPE01 bonds mature on 28 April 2023. For further information, please contact: Media: media@dno.no (mailto:media@dno.no) Investors: investor.relations@dno.no (mailto:investor.relations@dno.no) Tel: +47 23 23 84 80 -- DNO ASA is a Norwegian oil and gas operator focused on the Middle East-North Africa region and the North Sea. Founded in 1971 and listed on the Oslo Stock Exchange, the Company holds stakes in onshore and offshore licenses at various stages of exploration, development and production in the Kurdista

Vaisala Digital Renews Focus and Reorganizes Operations22.8.2019 16:30:00 CESTPress release

Vaisala Press Release August 22, 2019 Vaisala Digital Renews Focus and Reorganizes Operations To drive business performance and innovation speed, Vaisala Digital focuses on transportation, renewable energy, lightning, and data-driven operations, steps up its investments in development, and reorganizes its structure and operations. Vaisala sets a new direction for its digital business with investments into new assets, capabilities, and structure to develop industry leading digital solutions to support its customers to make best decisions in weather critical operations. In addition to the recently announced acquisition of Foreca’s professional B2B weather services business, Vaisala focuses on building up enhanced competences in machine learning and artificial intelligence, consolidates its data centers into two locations, and opens a new Vaisala Digital site in Keilaniemi, Espoo, to drive co-innovation with the software research and development community. “The acquisition of Foreca’s pro

Avance Gas Holding Ltd – Notice of Annual General Meeting22.8.2019 16:27:00 CESTPress release

Avance Gas Holding Ltd – Notice of Annual General Meeting Avance Gas Holding Ltd (OSE: AVANCE) announces that its 2019 Annual General Meeting will be held on September 13, 2019. A copy of the Notice of Annual General Meeting and including the Company`s Consolidated Financial Statements for 2018 can be found in the links below and on our website at www.avancegas.com. For further queries, please contact: Peder C. G. Simonsen, CFO Tel: +47 22 00 48 15 / Email: p.simonsen@avancegas.com ABOUT AVANCE GAS Avance Gas operates in the global market for transportation of liquefied petroleum gas (LPG). The Company is one of the world's leading owners and operators of very large gas carriers (VLGC), and operates a fleet of fourteen modern ships For more information about Avance Gas, please visit: www.avancegas.com. This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act. Attachments AGM Notice Avance Gas Avance Gas Annual-Report-20

Stämmokommuniké från extra bolagsstämma i Vostok New Ventures Ltd22.8.2019 16:00:00 CESTPressemelding

Extra bolagsstämma i Vostok New Ventures Ltd (”Bolaget”) hölls onsdagen den 22 augusti 2019 kl. 14.00 i Advokatfirman Vinges lokaler, Stureplan 8 i Stockholm. Stockholm, Aug. 22, 2019 (GLOBE NEWSWIRE) -- På extra bolagsstämma hade aktieägarna att ta ställning till om ett nytt aktiebaserat incitamentsprogram skulle antas för vissa ledande befattningshavare och nyckelpersoner inom Vostok New Ventures-koncernen. Följande beslut fattades: Stämman beslutade, i enlighet med styrelsens förslag, att anta ett femårigt prestationsbaserat incitamentsprogram som bygger på samma ekonomiska egenskaper för deltagarna och samma kriterier för att mäta prestation som de befintliga SDB-baserade incitamentsprogrammen, men som har utformats för att minska kostnaderna såväl för Bolaget som för deltagarna. Stämman beslutade, i enlighet med styrelsens förslag, att ändra Bolagets Bye-Laws (bolagsordning), varigenom en ny aktieklass, incitamentsaktier, införs. Stämman beslutade, i enlighet med styrelsens försla